INmune Historical Financial Ratios
| INMB Stock | USD 11.84 0.07 0.59% |
INmune Bio is lately reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 5.57 or Days Sales Outstanding of 5.5 K will help investors to properly organize and evaluate INmune Bio financial condition quickly.
INmune |
About INmune Financial Ratios Analysis
INmune BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate INmune Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on INmune financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across INmune Bio history.
INmune Bio Financial Ratios Chart
INmune Bio financial ratios usually calculated using numerical values taken directly from INmune Bio financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about INmune Bio. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At present, INmune Bio's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Invested Capital is expected to grow to 0.29, whereas Price To Sales Ratio is forecasted to decline to 1,241. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing INmune Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on INmune Bio sales, a figure that is much harder to manipulate than other INmune Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from INmune Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.At present, INmune Bio's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Invested Capital is expected to grow to 0.29, whereas Price To Sales Ratio is forecasted to decline to 1,241.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 14.51 | 10.98 | 8.92 | 5.75 | Receivables Turnover | 0.0329 | 0.0442 | 0.0635 | 0.0603 |
INmune Bio fundamentals Correlations
Click cells to compare fundamentals
INmune Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
INmune Bio fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 2.52 | 5.33 | 2.05 | 1.89 | 5.31 | 5.57 | |
| Book Value Per Share | 2.3 | 3.23 | 4.97 | 3.35 | 2.12 | 1.9 | |
| Free Cash Flow Yield | (0.0904) | (0.0433) | (0.26) | (0.2) | (0.0592) | (0.0621) | |
| Operating Cash Flow Per Share | (0.52) | (0.75) | (1.77) | (1.27) | (0.67) | (0.7) | |
| Pb Ratio | 2.52 | 5.33 | 2.05 | 1.89 | 5.31 | 5.57 | |
| Free Cash Flow Per Share | (0.52) | (0.75) | (2.7) | (1.27) | (0.67) | (0.7) | |
| Roic | (0.39) | 0.003346 | (0.0119) | (0.36) | (0.005448) | (0.00572) | |
| Net Income Per Share | (0.89) | (1.01) | (1.88) | (1.6) | (1.67) | (1.75) | |
| Cash Per Share | 0.68 | 1.83 | 4.64 | 2.91 | 1.99 | 1.22 | |
| Pocfratio | (11.07) | (23.08) | (5.77) | (5.01) | (16.9) | (17.75) | |
| Pfcf Ratio | (11.07) | (23.08) | (3.78) | (5.01) | (16.9) | (17.75) | |
| Income Quality | 0.7 | 0.74 | 0.94 | 0.83 | 0.4 | 0.38 | |
| Roe | (0.75) | (0.39) | (0.31) | (0.38) | (0.48) | (0.79) | |
| Ev To Operating Cash Flow | (9.8) | (20.64) | (3.68) | (3.39) | (14.78) | (15.52) | |
| Pe Ratio | (6.52) | (17.06) | (5.42) | (3.97) | (6.75) | (7.08) | |
| Return On Tangible Assets | (14.65) | (1.15) | (0.5) | (0.36) | (0.74) | (0.78) | |
| Ev To Free Cash Flow | (9.8) | (20.64) | (2.41) | (3.39) | (14.78) | (15.52) | |
| Earnings Yield | (0.14) | (0.15) | (0.0586) | (0.18) | (0.25) | (0.16) | |
| Intangibles To Total Assets | 0.67 | 0.41 | 0.17 | 0.2 | 0.29 | 0.56 | |
| Net Debt To E B I T D A | 0.63 | 1.78 | 2.04 | 1.42 | 0.85 | 0.68 | |
| Current Ratio | 11.09 | 13.5 | 18.95 | 5.92 | 2.16 | 2.05 | |
| Tangible Book Value Per Share | 0.69 | 1.86 | 3.95 | 2.43 | 1.2 | 1.02 | |
| Graham Number | 6.78 | 8.57 | 14.51 | 10.98 | 8.92 | 5.75 | |
| Shareholders Equity Per Share | 2.3 | 3.23 | 4.97 | 3.35 | 2.12 | 1.9 | |
| Graham Net Net | (36.79) | (82.4) | 3.5 | 2.05 | 1.05 | 1.1 | |
| Enterprise Value Over E B I T D A | (4.87) | (15.1) | (3.6) | (2.96) | (5.95) | (6.25) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.